ICD Benefits in the Ejection-Fraction Border Zone

In a cross-registry cohort of patients with LVEFs between 30% and 35%, mortality was significantly lower in those who received a device than in those who did not.

Randomized controlled trials (RCTs) of implantable cardioverter-defibrillators (ICDs) in patients with cardiomyopathies have generally restricted enrollment to those with left ventricular ejection fractions (LVEFs) of <35%. Yet the median LVEF in these trials is typically well below 30%. Do patients with LVEFs between 30% and 35% derive as much benefit from ICDs as those with lower LVEFs?

In a retrospective cohort study, 408 patients enrolled in the National Cardiovascular Data Registry ICD Registry with LVEFs of 30% to 35% were matched with the same number of patients enrolled in the American Heart Association's Get With The Guidelines–Heart Failure registry who had similar LVEFs but did not undergo ICD implantation. Adjusted 1-year mortali…

Reviewing Author

Mark S. Link, MD

Disclosures

Editorial BoardsCirculation; UpToDate

Mark S. Link, MD

Disclosures

Editorial BoardsCirculation; UpToDate

ICD Benefits in the Ejection-Fraction Border Zone

Topics

Reviewing Author